SmartMed Technologies’ Research and Development Division, after a detailed report, expect hydrogen to grow at a CAGR of 5.8% by 2025 due to the growing demand for renewable energy sources.

SmartMed Technologies’ analysts concluded that the ever-increasing adoption of hydrogen and the importance of energy conservation which is raising awareness globally, is expected to boost the global market for hydrogen due to the shift from fossil fuels to renewable fuels.

SmartMed Technologies’ Chief Technology Officer, Mr. Bayard Donovan commented on the hydrogen report saying “Hydrogen is arguably one of the most abundant available elements on earth and it is of paramount importance to industries such as agriculture, fertilizer and chemical manufacturing, and pharmaceutical production among many others.”

“Hydrogen is the fastest growing energy source with a current CAGR of 8.7%. We believe that over the next 15-20 years, hydrogen will be on par with electricity as an effective energy source. Numerous countries are adopting stringent regulations to reduce the use of conventional fossil fuels responsible for excessive greenhouse gas emissions,” added Bayard Donovan, Chief Technology Officer of SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.